0

Explore original, structured summaries for research and education.

Research profile

VIP(Vasoactive Intestinal Polypeptide)

(Vasoactive Intestinal Polypeptide)

VIP(Vasoactive Intestinal Polypeptide) is indexed as a Neuropeptide research entry. Its current evidence category is (Vasoactive Intestinal Polypeptide), and published discussion commonly places it within Cognitive, Immune. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.

CognitiveImmune

Identity

Molecular Data

Molecular weight
3,326 Da
Chain length
28 amino acids
Type
Neuropeptide
Reported half-life
1-2 minutes
Amino-acid sequenceHis-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2

Literature map

Research indications

Cardiovascular

  • Pulmonary Hypertensionmost effective
  • Vasodilationmost effective
  • Cardiac Supporteffective

Neurological

  • Neuroprotectionmoderate
  • Autism Spectrum Disordersemerging
  • Circadian Rhythmmoderate

Metabolic & Immune

  • Diabetes Supportmoderate
  • Anti-Inflammatoryeffective
  • Sarcoidosismoderate

Evidence-gated guidance

Dosing Protocols

No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.

Dose
Not established on this profile
Frequency
Not established on this profile
Cycle
Not established on this profile
Storage
Follow the exact supplier or authorized product documentation; requirements vary by formulation
Open peptide calculator →

Combination risks

Interactions

Evidence status

No independently verified interaction table is available here for VIP(Vasoactive Intestinal Polypeptide). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.

Do not infer compatibility

Being listed beside another compound does not mean that combining them is safe or effective.

Evidence-informed overview

What to Expect

Evidence boundary

Research indications describe topics studied in the literature; they do not predict an individual outcome.

Clinical monitoring

Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.

Risk overview

Side Effects & Safety

The safety profile of VIP(Vasoactive Intestinal Polypeptide) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.

Verification

Quality Checklist

  1. Confirm exact chemical identity, sequence, salt form, and concentration.
  2. Require a batch-specific certificate of analysis with named test methods and results.
  3. Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
  4. For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.

Clear answers

Frequently Asked Questions

Is VIP(Vasoactive Intestinal Polypeptide) approved for personal use?

This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.

Why is no dose listed?

A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.

Do research indications prove effectiveness?

No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.

Source trail

References

  1. VIP as New Drug for Treatment of Primary Pulmonary HypertensionJournal of Clinical Investigation · 2003
  2. Therapeutic Potential of VIP and VPAC2 in Type 2 DiabetesFrontiers in Endocrinology · 2022
  3. Therapeutic Potential of VIP in Neurological DisordersCNS Neuroscience & Therapeutics · 2010
  4. VIP Structure and Function for Therapeutic ApplicationsPharmacology & Therapeutics · 2011

View the structural source profile ↗